Clinical trial
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
NCT06650579
Study timeline
Study start (actual)2025-01-31Date precision: day
Registry last updated2026-02-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Recurrent Prostate Carcinomaunresolved
Stage III Prostate Cancer AJCC v8unresolved
Stage IVA Prostate Cancer AJCC v8unresolved
Interventions
Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate
BicalutamideDRUG · verified · RxNorm: bicalutamide
Biospecimen CollectionPROCEDURE
Computed Tomography AngiographyPROCEDURE
LeuprolideDRUG · verified · RxNorm: leuprolide
PrednisoneDRUG · verified · RxNorm: prednisone
Radiation TherapyRADIATION
RelugolixDRUG · verified · RxNorm: relugolix
Sponsors & collaborators
Emory Universitylead sponsor
Pfizercollaborator
Sumitomo Pharma America, Inc.collaborator
National Comprehensive Cancer Networkcollaborator
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06650579 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.